The Complement C3 pipeline drugs market research report outlays comprehensive information on the Complement C3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Complement C3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Immunology, Genito Urinary System, and Hematological Disorders which include the indications Geographic Atrophy, Unspecified Ophthalmological Disorders, Autoimmune Disorders, Inflammation, IgA Nephropathy (Berger’s Disease), Glomerulonephritis, and Paroxysmal Nocturnal Hemoglobinuria. It also reviews key players involved in Complement C3 targeted therapeutics development with respective active and dormant or discontinued products.
The Complement C3 pipeline targets constitutes close to 31 molecules. Out of which, approximately 29 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 7, 14, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
Complement C3 overview
Complement C3 (C3) is a protein in the immune system that is found in the blood. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation, C3b can bind covalently via its reactive thioester to cell surface carbohydrates or immune aggregates.
For a complete picture of Complement C3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
